Columbia University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Columbia University sits in the top decile of US sponsors by registered trial count (#34 of 15,742 sponsors by registered trial count).
Columbia University: 958 sponsored US clinical trials, 171 recruiting.
Columbia University sponsors 958 registered US clinical trials on ClinicalTrials.gov, 171 of them currently recruiting, and 597 completed. 88 of these trials are in Phase 3-4 (later-stage) and 191 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 9 trials.
Top-decile sponsor footprint
Columbia University ranks in the top decile of sponsors by registered trial count (#34 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
597 of 736 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
958 total, page 8 of 20
Postpartum Oxytocin Administration in the Era of Delayed Cord Clamping
NCT04632264
RNA Precision Oncology in Advanced Pancreatic Cancer
NCT04476537
The Care After Life-threatening Medical Events Study
NCT04589559
Telehealth After Stroke Care: Integrated Multidisciplinary Access to Post-stroke Care
NCT04640519
Cerebrospinal Fluid Biomarkers in Bariatric Surgery
NCT04350892
Smoking Cessation Pilot for People Living With HIV (PLWH)
NCT04808609
IV Contrast-Enhanced Cone Beam Computed Tomography (CBCT) in Radiotherapy
NCT04199754
Daily Vitamin D for Sickle-cell Respiratory Complications
NCT04170348
Practical Approaches to Care in Emergency Syncope
NCT04533425
Technology Development for Noninvasive Prenatal Genetic Diagnosis Using Whole Fetal Cells From Maternal Peripheral Blood
NCT04285814
Doppler Ultrasound Compared With Stethoscope to Assess Heart Rate (HR)
NCT04242654
Non-invasive Blood-brain Barrier Opening in Alzheimer's Disease Patients Using Focused Ultrasound
NCT04118764
(CONCERN) Clinical Decision Support (CDS) System
NCT03911687
Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
NCT04381052
SUNLIGHT Study: Online Support Groups for MS to Address COVID-19
NCT04379661
Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19
NCT04367831
Pediatrics HOT COVID-19 Database in NY Tristate
NCT04445402
Well-being Promotion and Sleep Hygiene Education to Improve Sleep Quality
NCT04316663
Saved From COVID-19 - Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID
NCT04349371
Awake Proning in COVID-19 Patients With Hypoxemic Respiratory Failure
NCT04408222
Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19
NCT04347226
Social Activity, Loneliness and Stigma During COVID-19 Outbreak
NCT04734171
Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)
NCT04318444
Acquiring Convalescent Specimens for COVID-19 Antibodies
NCT04342195
Prebiotic vs Probiotic in Multiple Sclerosis
NCT04038541
Amantadine in Treating Cognitive & Motor Impairments in Adolescents and Adults With Cerebral Palsy
NCT04273737
Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer
NCT04301414
Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies
NCT04214418
Weekly Antepartum Testing in Women With BMI 30-40 and Neonatal Outcomes
NCT04180566
Circulating Tumor DNA Alterations in Non-small Cell Lung Cancer Patients Treated With Pembrolizumab
NCT04791215
An Anesthesia-Centered Bundle to Reduce Postoperative Pulmonary Complications: The PRIME-AIR Study
NCT04108130
BabyQ's: Randomized Controlled Trial of Health Messaging in Pregnancy and Infancy
NCT04238585
Family-Based Intervention Study of the Effects of Environmental Exposures on Breast Tissue Composition
NCT04265547
Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease
NCT04070781
Dynamically Tailored Behavioral Interventions in Diabetes
NCT04226027
Smartphone App for Cancer Medication Adherence
NCT05225090
Preventing Drug Abuse Among Sexual Minority Youth
NCT03954535
Ataxia and Exercise Disease Using MRI and Gait Analysis
NCT03701776
Survey of Correction Officers Before and After a Targeted Education Campaign
NCT05451225
Clinical Interviews With Detainees With Early Psychosis
NCT03962348
Clinical Interventions to Mitigate Neurodevelopmental Risk
NCT04233489
Cognitive Multi-Tasking Training in Healthy Older Adults
NCT04195230
Skeletal Fragility in Type 1 Diabetes: Glycemic Control and Bone Strength
NCT04289727
Art Therapy Pain Management Adolescents Pediatric ED
NCT03755687
Wearable Technology to Assess Gait Function in SMA and DMD
NCT04193085
Glucose Monitoring During Chemotherapy
NCT04473378
The Effect of Maternal Scent on Sleep Wake States
NCT04301453
AI Mobile Application Versus HCP for Bodyweight Squats
NCT04624594
Inulin for Infections in the Intensive Care Unit
NCT03865706
Information Visualizations to Facilitate HIV-related Patient-provider Communication in New York City (Info Viz: HIV-NYC)
NCT04102540
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 86 |
| Phase 2 | 105 |
| Phase 3 | 23 |
| Phase 4 | 65 |
Therapeutic Areas
What is open in the Columbia University pipeline
171 recruiting of 958 indexed (18% open); 597 completed (62%).
Phase mix: 88 late (III/IV) vs 191 early (I/II) (early-phase heavy).
Top condition: Obesity (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Columbia University: open-pipeline peers nationwide
Peers matched on 958 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
Columbia University sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 958 trials (± recruiting share)
- University of Minnesota · 966 trials · 19% recruiting
- Brigham and Women's Hospital · 937 trials · 15% recruiting
- Hoffmann-La Roche · 909 trials · 8% recruiting
- University of California, Los Angeles · 897 trials · 18% recruiting
Sponsors near 18% open enrollment (± trial volume)
- Kite, A Gilead Company · 18% recruiting · 28 trials
- Mirum Pharmaceuticals · 18% recruiting · 28 trials
- West Virginia University · 18% recruiting · 122 trials
- Hospital for Special Surgery, New York · 18% recruiting · 194 trials
Related
What to do with this Columbia University page
958 registered trials is a research-attention snapshot, not an endorsement of Columbia University or any single study.
- 171 of Columbia University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition Columbia University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Columbia University pipeline card: 958 registered trials from official public datasets.Report a data error.